Subscribe To
Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee
A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...
December 11, 2022, 3:00 pm
Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee
A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...
December 11, 2022, 3:00 pm
Igm biosciences presents data from t cell engager portfolio for hematologic malignancies at 2022 american society of hematology annual meeting
First preclinical Data for IGM-2644 and IGM-2537 Featured in Poster Presentations MOUNTAIN VIEW, Calif....
December 11, 2022, 3:00 pm
Senti bio highlights preclinical data from logic-gated gene circuit car-nk cell therapy senti-202 at ash annual meeting and investor event
– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell th...
December 11, 2022, 2:00 pm
Fate therapeutics highlights ipsc-derived, off-the-shelf car nk cell programs for multiple myeloma at 2022 ash annual meeting
Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose Escalation Cohorts as Monotherapy and in C...
December 10, 2022, 7:46 pm
Synaptogenix: bryostatin for alzheimer's, as binary as can be
Synaptogenix has announced a readout of a Phase 2 randomized placebo-controlled trial in Alzheimer's disease for the current quarter. ...
December 9, 2022, 11:50 am
Entrada therapeutics shares jump on collaboration with vertex
Shares of Entrada Therapeutics Inc. TRDA, +3.20% rallied 15% in premarket trading on Thursday after the company announced a deal with Vertex Pharmaceu...
December 8, 2022, 8:24 am
Betterlife pharma closes private placement with help from negev capital to fuel clinical programs
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) announced that it has closed a financing designed to advance its clinical and ...
December 7, 2022, 9:42 am
Adding multimedia mymd pharmaceuticals® to present data on oral tnf-a inhibitor mymd-1® at the british society for immunology (bsi) congress 2022
BALTIMORE--( BUSINESS WIRE )--MyMD Pharmaceuticals, Inc. ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical compa...
December 6, 2022, 9:40 am
Betterlife to present betr-001 preclinical data at the american college of neuropsychopharmacology meeting in phoenix
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) said that one of its scientific collaborators, Dr Argel Aguilar-Valles from Carleton University's Depart...
December 2, 2022, 9:25 am
Medgene therapeutics publishes preclinical data demonstrating riv-8’s ability to overcome t cell exhaustion in the journal science advances
RIV-8 is a breakthrough technology to address T cell exhaustion GAITHERSBURG, Md., Nov. 29, 2022 (GLOBE NEWSWIRE) — MedGene Therapeutics, Inc. (MedG...
November 29, 2022, 10:00 pm
Athira pharma to present preclinical data highlighting therapeutic potential of ath-1105 in als at the 33rd international symposium on als/mnd
HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS HGF/MET small ...
November 28, 2022, 7:00 am
Imugene’s oncarlytics combination with celularity’s placental-derived off-the-shelf allogeneic cycart-19 t cells preclinical data presented at sitc annual meeting
SYDNEY, Australia and FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) — Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company and C...
November 10, 2022, 10:00 pm
Bicycle therapeutics to present five posters highlighting preclinical data from its bicycle tumor-targeted immune cell agonist® (bicycle tica®) programs at the sitc 37th annual meeting
CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated cla...
November 10, 2022, 9:09 am
Abcellera biologics: q3 commentary - moving up the value stack
AbCellera reported its Q3 earnings on November 8th, solidly beating estimates on both the top and bottom lines. The company, in the days before the re...
November 9, 2022, 1:45 am
Nuvectis pharma, inc. reports third quarter 2022 financial results and business highlights
The dose escalation portion of the Phase 1 clinical trial of NXP800 is ongoing, and the Phase 1b dose expansion portion is expected to begin in Q1 202...
November 8, 2022, 1:00 pm
Cytomx therapeutics to present preclinical data for conditionally activated interferon alpha-2b (cx-801) at the sitc 2022 annual meeting
- IND filing for CX-801 is anticipated in the second half of 2023 - - IND filing for CX-801 is anticipated in the second half of 2023 -...
November 7, 2022, 4:15 pm
Schrödinger to present new preclinical data from its cdc7 inhibitor program at american society of hematology 2022 annual meeting
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and mate...
November 3, 2022, 9:23 am
Nuvalent to present preliminary phase 1 data from arros-1 clinical trial of nvl-520 at 34th eortc-nci-aacr symposium and announces pipeline updates
Preliminary Dose Escalation Data on ROS1-selective Inhibitor NVL-520 to be Presented in the "New Drugs on the Horizon" Oral Plenary Session New ...
September 7, 2022, 6:30 am
Tyra biosciences to present preclinical data on tyra-300, an fgfr3-selective inhibitor, at esmo 2022 congress
CARLSBAD, Calif. , Sept. 5, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-bui...
September 5, 2022, 8:15 am